Literature DB >> 34993581

A comprehensive review on phytochemicals for fatty liver: are they potential adjuvants?

Taís Menezes do Moinho1, Sandro Leão Matos1, Carla R O Carvalho2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome and, as such, is associated with obesity. With the current and growing epidemic of obesity, NAFLD is already considered the most common liver disease in the world. Currently, there is no official treatment for the disease besides weight loss. Although there are a few synthetic drugs currently being studied, there is also an abundance of herbal products that could also be used for treatment. With the World Health Organization (WHO) traditional medicine strategy (2014-2023) in mind, this review aims to analyze the mechanisms of action of some of these herbal products, as well as evaluate toxicity and herb-drug interactions available in literature.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Fatty liver; Metabolic syndrome; NAFLD; Phytochemicals; Traditional medicine

Mesh:

Substances:

Year:  2022        PMID: 34993581     DOI: 10.1007/s00109-021-02170-3

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  100 in total

1.  The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

Review 2.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

Review 3.  Obesity and the nutrition transition in Sub-Saharan Africa.

Authors:  Nelia P Steyn; Zandile J McHiza
Journal:  Ann N Y Acad Sci       Date:  2014-04       Impact factor: 5.691

Review 4.  Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.

Authors:  Vignan Manne; Priya Handa; Kris V Kowdley
Journal:  Clin Liver Dis       Date:  2017-10-18       Impact factor: 6.126

Review 5.  Obesity and hypertension in Latin America: Current perspectives.

Authors:  L M Ruilope; A C B Nunes Filho; W Nadruz; F F Rodríguez Rosales; J Verdejo-Paris
Journal:  Hipertens Riesgo Vasc       Date:  2018-02-01

6.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Authors:  Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

Review 7.  Pathogenesis of nonalcoholic steatohepatitis.

Authors:  Wensheng Liu; Robert D Baker; Tavleen Bhatia; Lixin Zhu; Susan S Baker
Journal:  Cell Mol Life Sci       Date:  2016-02-19       Impact factor: 9.261

Review 8.  Obesity in South Africa.

Authors:  M-T van der Merwe; M S Pepper
Journal:  Obes Rev       Date:  2006-11       Impact factor: 9.213

9.  Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Authors:  Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

Review 10.  Obesity and its health impact in Africa: a systematic review.

Authors:  Bridget Adeboye; Giovanna Bermano; Catherine Rolland
Journal:  Cardiovasc J Afr       Date:  2012-10       Impact factor: 1.167

View more
  1 in total

Review 1.  Biogenic Phytochemicals Modulating Obesity: From Molecular Mechanism to Preventive and Therapeutic Approaches.

Authors:  Vikram Kumar; Desh Deepak Singh; Sudarshan Singh Lakhawat; Nusrath Yasmeen; Aishwarya Pandey; Rajeev K Singla
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-27       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.